187 related articles for article (PubMed ID: 7624837)
1. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Kotani I; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Thromb Res; 1995 Mar; 77(6):493-504. PubMed ID: 7624837
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease.
Günther A; Mosavi P; Ruppert C; Heinemann S; Temmesfeld B; Velcovsky HG; Morr H; Grimminger F; Walmrath D; Seeger W
Thromb Haemost; 2000 Jun; 83(6):853-60. PubMed ID: 10896238
[TBL] [Abstract][Full Text] [Related]
3. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
Xiao W; Tong WL; Ma DD
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
[TBL] [Abstract][Full Text] [Related]
4. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis.
Senoo T; Hattori N; Tanimoto T; Furonaka M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Yokoyama A; Kohno N
Thorax; 2010 Apr; 65(4):334-40. PubMed ID: 20388759
[TBL] [Abstract][Full Text] [Related]
5. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma.
Semeraro N; Montemurro P; Giordano P; Santoro N; De Mattia D; Colucci M
Thromb Haemost; 1994 Jul; 72(1):54-7. PubMed ID: 7974375
[TBL] [Abstract][Full Text] [Related]
6. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
[TBL] [Abstract][Full Text] [Related]
7. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
9. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
10. Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.
Maris NA; de Vos AF; Bresser P; van der Zee JS; Jansen HM; Levi M; van der Poll T
Crit Care Med; 2007 Jan; 35(1):57-63. PubMed ID: 17080003
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
16. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis.
Fujii M; Hayakawa H; Urano T; Sato A; Chida K; Nakamura H; Takada A
Thromb Res; 2000 Jul; 99(2):111-7. PubMed ID: 10946084
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival crevicular fluid from patients with Papillon-Lefèvre syndrome.
Ullbro C; Kinnby B; Lindberg P; Matsson L
J Clin Periodontol; 2004 Sep; 31(9):708-12. PubMed ID: 15312091
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
19. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.
Colucci M; Gesualdo L; Montemurro P; Cavallo LG; Conese M; Mascolo E; Ranieri E; Di Paolo S; Schena FP; Semeraro N
Thromb Haemost; 1995 Dec; 74(6):1516-20. PubMed ID: 8772230
[TBL] [Abstract][Full Text] [Related]
20. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
